article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. In addition to advising on EU life sciences matters, Maarten also handles competition litigation at the EU and national levels. Maarten has significant competition law experience in a variety of sectors.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Safety 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Directive 2001/83 (as amended). The Impact of Biosimilar Competition in Europe, IQVIA, December 2021. EMA Biosimilars Q&A.

article thumbnail

Using alkali-metal cation recognition of ?-cyclodextrin to detect lithium ions by MALDI-TOF

European Pharmaceutical Review

1,7 It may depend on the competition between 6 Li and 7 Li, present at much higher concentration, to be ionised. Following post-doctoral studies on proteomics at Purdue University, under supervision of Professor Fred E Regnier, Ahmad joined the SMPA laboratory in 2001. percent and 7.5= Schalley CA. Lee JU, Lee SS, Lee S, et al.,

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. Salsify offers competitive benefits and a flexible vacation plan. Founded 2001. Cybereason is a cybersecurity platform that provides advanced cyber threat hunting and detection. Devoted Health. Founded 2017.

Sales 76
article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.